Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- KERR D. N., DAVIDSON S. Gastrointestinal intolerance to oral iron preparations. Lancet. 1958 Sep 6;2(7045):489–492. doi: 10.1016/s0140-6736(58)91282-0. [DOI] [PubMed] [Google Scholar]
- KUZELL W. C., SCHAFFARZICK R. W., NAUGLER W. E., GAUDIN G., MANKLE E. A. Phenylbutazone; further clinical evaluation. AMA Arch Intern Med. 1953 Nov;92(5):646–661. doi: 10.1001/archinte.1953.00240230046005. [DOI] [PubMed] [Google Scholar]
- MASON R. M., HAYTER R. R. The present status of phenylbutazone therapy in rheumatic disease. Practitioner. 1958 Jul;181(1081):23–28. [PubMed] [Google Scholar]
- MAUER E. F. The toxic effects of phenylbutazone (butazolidin); review of the literature and report of the twenty-third death following its use. N Engl J Med. 1955 Sep 8;253(10):404–410. doi: 10.1056/NEJM195509082531003. [DOI] [PubMed] [Google Scholar]
- O'BRIEN D. J., STOREY G. Death from hypersensitivity due to phenylbutazone. Br Med J. 1954 Apr 3;1(4865):792–794. doi: 10.1136/bmj.1.4865.792. [DOI] [PMC free article] [PubMed] [Google Scholar]
- SMYTH C. J., CLARK G. M. Phenylbutazone in rheumatoid arthritis. J Chronic Dis. 1957 Jun;5(6):734–750. doi: 10.1016/0021-9681(57)90081-4. [DOI] [PubMed] [Google Scholar]
- SPERLING I. L. Untoward effects of phenylbutazone (butazolidin)-a re-evaluation. Arthritis Rheum. 1959 Jun;2(3):203–211. doi: 10.1002/1529-0131(195906)2:3<203::aid-art1780020303>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]